Be the first to review this item
Phlogenzym is a new generation medicinal product consisting of a combination of highly active proteolytic enzymes (enzymes) of plant and animal origin, bromelain and trypsin in combination with routine. In combination, the enzymes exert a pleiotropic (multiple) action, having a variety of pharmacological actions on pathophysiological and biochemical processes. Enzymes of the drug realize their therapeutic effects through anti-inflammatory, immunomodulating, antiaggregant, fibrinolytic, thrombolytic, decongestant and secondary analgesic actions. The tablets of the drug, coated with an enteric coating, transitively pass the upper sections of the gastrointestinal tract, not injuring the stomach, are absorbed in the small intestine by resorption of intact molecules (endocytosis, pinocytosis). Proteases of the drug, binding to blood transport proteins (α-2-macroglobulin and α-1-antitrypsin) form a reversible protease-antiprotease complex in which the antigenic determinants of exogenous proteases of the preparation are masked, which prevents allergic reactions. As a result of formation of a complex with enzymes, antiprotease (α-2-macroglobulin) passes into the active form, which serves as an extracellular regulator of pro-inflammatory cytokines and growth factors, carrying out their transfer, clearance and elimination.
The formation of an active protease-antiprotease complex allows the proteolytic enzymes to be safely moved along the vascular bed to the site of inflammation and to the site of injury, regardless of the site of localization in the body. The complex keeps and slows the removal of proteolytic enzymes of the drug from the body, increases the time of their circulation in the vascular bed and, accordingly, the therapeutic effect. Getting into the inflammatory focus and wounds, proteolytic enzymes break down (hydrolyse) damaged proteins, tissues and eliminate (remove) cellular debris (detritus), contributing to the acceleration of the cleansing and healing of the wound.
The drug positively affects the course of the inflammatory process, modulates the protective reactions of the body, which contributes to the physiological course of inflammation at different stages. Proteolytic enzymes of the drug accelerate the disintegration of inflammatory mediators, cleave immune complexes and membrane deposits, increase the activity of phagocytes, natural killer cells, stimulate interferonogenesis. Proteases of the drug reduce the level of proinflammatory cytokines (IL-1β, IL-6, IL-8, INF-γ, TNF-α) and promote the production of anti-inflammatory cytokines (including IL-4, IL-10), regulate the level Ig and antibodies of blood. Enzymes of the drug limit the pathological manifestations of autoimmune and immunocomplex processes, restore the immunological reactivity of the organism.
Protease drugs reduce the level of transforming growth factor β, the increase of which leads to excessive scarring. Proteolytic enzymes have a regulatory effect on the synchronization of the formation of the basement membrane (laminin), the modulation of the wound process and the expression of angiogenesis factors (vasculoendothelial growth factor, fibroblast growth factor and a number of other factors). Thus, the enzymes of the drug contribute to the improvement of reparative processes, the prevention of the formation of hypertrophic and keloid scars, the development of adhesions after surgical interventions on the abdominal cavity.
Enzymes of the drug cleave and remove damaged tissues, accelerate resorption of hematomas and edema due to normalization of permeability of the vessel walls, reduction of infiltration of interstitium by plasma proteins, increase in elimination of protein detritus and fibrin deposits, improvement of microcirculation and trophic processes in the area of injury. Optimization of the inflammatory process by proteolytic enzymes due to reduction of oncotic pressure and tissue edema, reduction of pressure on nerve endings, elimination of ischemia and normalization of microcirculation, direct proteolysis of inflammatory mediators allows proteases to exert a secondary analgesic effect. At the same time, proteolytic enzymes provide stimulation of healing and repair processes, reduce the risk of thromboembolic complications with prolonged immobilization, prevent the development of trophic disorders and suppurative complications.
Enzymes of the drug positively affect the improvement of microcirculation, increase the delivery of oxygen and nutrients to the wound, reduce inflammation in the lesion, maintain the physiological process of regeneration and accelerate the restoration of the function of organs and tissues.
The drug improves the rheological properties of blood (viscosity and fluidity) due to the positive effect on the functional state of blood cells and the vascular wall, plasticity (deformability) of erythrocytes, stabilization of the permeability of the endothelium, increased fibrinolytic activity of blood serum, a decrease in the density of adhesive molecules, reduced platelet aggregation .
Proteolytic enzymes reduce the number of activated forms of platelets (spheroehinocytes) and micro- and macroaggregates; reducing the risk of blood clots in the vessels, and simultaneously participate in the lysis of the formed blood clots. Proteolytic enzymes reduce the level of atherogenic lipids, promoting increased HDL, reducing the risk of atherosclerosis and vascular disorders.
The drug improves the blood supply to the bronchi and lung tissue in chronic respiratory diseases, incl. caused by smoking, improves the viscosity properties of bronchial secretion, the function of ciliated epithelium, restores the drainage function of the bronchi, dilutes sputum, which facilitates breathing and reduces cough.
Proteolytic enzymes of the drug increase the effectiveness of antibiotics while reducing unwanted effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). Proteases improve the cleavage of substrates, optimize the balance of microbiota, promote the restoration of endoecology of the intestine.
In complex therapy and prevention of the following diseases and conditions:
Take at least 30 minutes before eating, without sniffing, washing with water (200 ml). After the operation, the drug should be taken from the 2nd-3rd day.
Treatment. The drug is taken after trauma and surgery or acute inflammation for the cleavage and removal of damaged tissues, resorption of hematomas, improvement of trophic tissue and repair processes, reducing inflammation and edema, reducing the risk of complications - thrombosis, development of adhesive disease, keloid scar formation and wound suppuration: 3 tablets 3 times a day for 2 weeks. If necessary, to improve recovery and healing, the course of taking the drug can be prolonged up to 4 weeks and more 2 tablets 3 times a day.
Prevention of complications. To prevent long-term consequences after the operation - thromboembolic complications, development of adhesive disease of the abdominal cavity, trophic disorders during prolonged bed rest and immobilization of the patient: the drug is recommended to take a long course in a dosage of 2 tablets 3 times a day for 4 weeks or more or for the whole period immobilization.
Use with antibiotics. When prescribing antibiotics, the drug is used to increase the effectiveness of antibiotic therapy and to reduce the undesirable effects of antibiotics. The drug is recommended to take throughout the course of antibiotic therapy 2 tablets 3 times a day.
Use with hormones. When appointing long courses of hormones, the drug is recommended to take 2 tablets 3 times a day for the whole course of taking hormonal medications to reduce the risk of complications (thrombosis). When prescribing hormone replacement therapy to reduce the risk of vein thrombosis of the lower extremities, the drug is recommended to take 2 tablets 3 times a day for repeated courses of 2 weeks with interruptions of 3 weeks 3-4 times a year.
Prevention. To prevent thrombosis of the veins of the lower limbs and reduce the risk of vascular accidents (infarction), the drug is recommended to take 2 tablets 3 times a day for at least 3-4 weeks, repeating the course of taking the drug 3-4 times a year.
Changing the course and dosages of the drug is recommended after consulting a doctor.
The drug is well tolerated by patients. In some cases, there may be more frequent stools, a change in consistency and odor of the stool, which quickly stop when the dosage of the drug is temporarily reduced. Occasionally, an allergic reaction may occur (skin rash, itching), which disappears after a dose reduction or drug withdrawal. If the conditions of application of the drug are violated, nausea, swelling and pain in the abdomen, headache, dizziness, exanthema, general weakness, sensation of fullness of the intestine may occur. These conditions disappear after a decrease in dosage or a temporary discontinuation of the drug.
In the case of infectious processes, Phlogenzym does not replace antibiotics.
In case of an acute exacerbation of the underlying disease, it is recommended that a temporary reduction in the dose of the drug or temporary withdrawal of the drug after consultation with the doctor is recommended.
Patients suffering from diabetes should note that each tablet contains 0.015 XE.
Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. The drug is not doping, does not have a negative impact on driving and performance of work requiring a high rate of mental and physical reactions.
Important notice- the outer box design may vary before prior notice!
Someone from the Brazil - just purchased the goods:
Zhenoluten 60 capsules